دورية أكاديمية
أعرض في EDS

Experimental diets dictate the metabolic benefits of probiotics in obesity.

التفاصيل البيبلوغرافية
العنوان: Experimental diets dictate the metabolic benefits of probiotics in obesity.
المؤلفون: Larsen IS; Quebec Heart and Lung Institute, Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada., Choi BS; Quebec Heart and Lung Institute, Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada., Föh B; Institute of Nutritional Medicine, University of Lübeck, Lübeck, Germany.; Department of Medicine I, University Hospital Schleswig-Holstein,Schleswih-Holstein, Germany., Kristensen NN; Novozymes A/S, Bagsvaerd, Denmark., Ouellette A; Quebec Heart and Lung Institute, Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada., Haller RF; Novozymes A/S, Bagsvaerd, Denmark., Olsen PB; Novozymes A/S, Bagsvaerd, Denmark., Saulnier D; Novozymes Berlin GmbH, Berlin, Germany., Sina C; Institute of Nutritional Medicine, University of Lübeck, Lübeck, Germany., Jensen BAH; Quebec Heart and Lung Institute, Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada.; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Marette A; Quebec Heart and Lung Institute, Faculty of Medicine, and Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada.
المصدر: Gut microbes [Gut Microbes] 2023 Jan-Dec; Vol. 15 (1), pp. 2192547.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101495343 Publication Model: Print Cited Medium: Internet ISSN: 1949-0984 (Electronic) Linking ISSN: 19490976 NLM ISO Abbreviation: Gut Microbes Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
مواضيع طبية MeSH: Non-alcoholic Fatty Liver Disease*/prevention & control , Gastrointestinal Microbiome* , Probiotics*/therapeutic use, Animals ; Mice ; Reproducibility of Results ; Obesity/microbiology ; Diet, High-Fat/adverse effects ; Mice, Inbred C57BL
مستخلص: Growing evidence supports the use of probiotics to prevent or mitigate obesity-related dysmetabolism and non-alcoholic fatty liver disease (NAFLD). However, frequent reports of responders versus non-responders to probiotic treatment warrant a better understanding of key modifiers of host-microbe interactions. The influence of host diet on probiotic efficacy, in particular against metabolic diseases, remains elusive. We fed C57BL6/J mice a low fat reference diet or one of two energy-matched high fat and high sucrose diets for 12 weeks; a classical high fat diet (HFD) and a customized fast food-mimicking diet (FFMD). During the studies, mice fed either obesogenic diet were gavaged daily with one of two probiotic lactic acid bacteria (LAB) strains previously classified as Lactobaccillus , namely Limosilactobacillus reuteri ( L. reuteri )or Lacticaseibacillus paracasei subsp. paracasei ( L. paracasei ), or vehicle. The tested probiotics exhibited a reproducible efficacy but dichotomous response according to the obesogenic diets used. Indeed, L. paracasei prevented weight gain, improved insulin sensitivity, and protected against NAFLD development in mice fed HFD, but not FFMD. Conversely, L. reuteri improved glucoregulatory capacity, reduced NAFLD development, and increased distal gut bile acid levels associated with changes in predicted functions of the gut microbiota exclusively in the context of FFMD-feeding. We found that the probiotic efficacy of two LAB strains is highly dependent on experimental obesogenic diets. These findings highlight the need to carefully consider the confounding impact of diet in order to improve both the reproducibility of preclinical probiotic studies and their clinical research translatability.
References: Nature. 2020 May;581(7809):475-479. (PMID: 32461639)
Science. 2021 Dec 24;374(6575):1632-1640. (PMID: 34941392)
Int J Obes (Lond). 2008 Oct;32(10):1537-44. (PMID: 18711387)
PLoS One. 2014 Dec 23;9(12):e115922. (PMID: 25535951)
Nat Commun. 2021 Feb 17;12(1):1093. (PMID: 33597537)
Lancet Public Health. 2017 May 19;2(6):e277-e285. (PMID: 28626830)
Hepatology. 2013 Feb;57(2):601-9. (PMID: 23055155)
Obes Rev. 2015 Feb;16 Suppl 1:1-6. (PMID: 25614198)
J Nutr Biochem. 2018 Apr;54:66-76. (PMID: 29268121)
Nucleic Acids Res. 2013 Jan 7;41(1):e1. (PMID: 22933715)
N Engl J Med. 1990 May 24;322(21):1483-7. (PMID: 2336075)
Environ Microbiol. 2014 Sep;16(9):2915-26. (PMID: 24118739)
Ann Pharmacother. 2020 Jul;54(7):691-705. (PMID: 31958967)
Hepatology. 2010 Feb;51(2):679-89. (PMID: 20041406)
J Hepatol. 2007 Oct;47(4):598-607. (PMID: 17692984)
Nat Rev Endocrinol. 2011 Aug 09;7(11):639-46. (PMID: 21826100)
Cell. 2018 Sep 6;174(6):1388-1405.e21. (PMID: 30193112)
Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365)
Gut Microbes. 2010 May-Jun;1(3):200-4. (PMID: 21637034)
Psychoneuroendocrinology. 2013 Sep;38(9):1738-47. (PMID: 23566632)
Diabetes Care. 2009 Nov;32 Suppl 2:S151-6. (PMID: 19875543)
Nat Metab. 2020 Mar;2(3):233-242. (PMID: 32694777)
Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314)
Gut. 2020 Oct;69(10):1796-1806. (PMID: 32317332)
Microorganisms. 2020 Jul 29;8(8):. (PMID: 32751306)
J Hepatol. 1995 Jun;22(6):696-9. (PMID: 7560864)
Cell Metab. 2015 Dec 1;22(6):971-82. (PMID: 26552345)
Cell Metab. 2005 Oct;2(4):217-25. (PMID: 16213224)
Br J Nutr. 2020 Oct 28;124(8):809-823. (PMID: 32498726)
Lipids. 2015 Oct;50(10):977-85. (PMID: 26294003)
Am J Physiol Gastrointest Liver Physiol. 2015 Oct 1;309(7):G528-41. (PMID: 26185332)
Nat Rev Microbiol. 2021 Feb;19(2):77-94. (PMID: 32968241)
Lancet. 2017 Jun 3;389(10085):2239-2251. (PMID: 28190580)
JAMA. 2020 Sep 1;324(9):879-887. (PMID: 32870301)
Curr Opin Microbiol. 2017 Oct;39:1-6. (PMID: 28783509)
J Cancer. 2020 Jul 20;11(19):5536-5546. (PMID: 32913449)
Front Nutr. 2022 Mar 11;9:851541. (PMID: 35369106)
Am J Physiol Gastrointest Liver Physiol. 2021 Jun 1;320(6):G1014-G1033. (PMID: 33881354)
Nature. 2022 Mar;603(7903):907-912. (PMID: 35296854)
J Hepatol. 2011 Sep;55(3):654-659. (PMID: 21172393)
BMJ. 2016 Mar 08;352:i582. (PMID: 26956984)
Gut Microbes. 2021 Jan-Dec;13(1):1988836. (PMID: 34693864)
Genome Med. 2016 May 10;8(1):52. (PMID: 27159972)
Nature. 2016 Jul 21;535(7612):376-81. (PMID: 27409811)
Gastroenterology. 2017 May;152(7):1718-1727.e3. (PMID: 28193517)
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):81. (PMID: 30647011)
Obes Rev. 2019 Feb;20(2):171-211. (PMID: 30324651)
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. (PMID: 24912386)
Food Funct. 2022 Jun 20;13(12):6688-6701. (PMID: 35647914)
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86. (PMID: 31756036)
معلومات مُعتمدة: FDN-143247 Canada CIHR; MRT-168045 Canada CIHR
فهرسة مساهمة: Keywords: MAFLD; NAFLD; NASH; Probiotics; diet-induced obesity; dietary interaction; insulin resistance; microbiota
تواريخ الأحداث: Date Created: 20230322 Date Completed: 20230323 Latest Revision: 20230328
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10038044
DOI: 10.1080/19490976.2023.2192547
PMID: 36945120
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-0984
DOI:10.1080/19490976.2023.2192547